Clovis study: Rubraca improves chances for ovarian cancer patients with BRCA mutation
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced data from the randomized, Phase 3 ARIEL4 study of Rubraca ® (rucaparib) demonstrate that Rubraca significantly improves PFS compared to... Read More
Tuesday March 23, 2021
Clovis Oncology submits Investigational New Drug applications to FDA for FAP-2286 for therapeutic and imaging clinical trial
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced it has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for... Read More
Tuesday December 29, 2020
Clovis Oncology: Rubraca meets primary endpoint of significantly improving progression-free survival vs. chemo in cancer study
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed... Read More
Monday December 21, 2020
Clovis: FDA approves FoundationOne Liquid CDx to serve as Rubraca companion diagnostic to identify eligible patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration approved the FoundationOne ® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test... Read More
Friday August 28, 2020
Clovis Oncology: First patient enrolled in Phase 2 of LIO-1 trial evaluating pairing Lucitanib, Opdivo
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’... Read More
Wednesday August 5, 2020
Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand... Read More
Wednesday June 17, 2020
Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca ... Read More
Thursday June 11, 2020
Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS), today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to... Read More
Friday May 29, 2020
IN Sponsors
Browse
Entrepreneurial by Nature
